Jubilant Pharmova Limited
All news and filings related to Jubilant Pharmova Limited.
View all news & filings- Medium impact
Jubilant Pharmova's Radiopharma business invests CAD 94.5 million to double RUBY-FILL® capacity.
Jubilant Pharmova's Radiopharma business will invest CAD 94.5 million to double production capacity of RUBY-FILL® at its Quebec facility. The Government of Canada will support this with CAD 23.8 million. This expansion addresses strong demand and enhances nuclear medicine capabilities.
Read the summary - Low impact
Jubilant Pharmova Files SEBI Certificate for Q2 FY27
Jubilant Pharmova Limited submitted a SEBI Regulation 74(5) certificate for the quarter ended September 30, 2026. The certificate from Alankit Assignments Limited confirms dematerialization of physical shares and updates to the company's records.
Read the summary - Low impact
Jubilant Pharmova: Trading Window Closed Oct 1, 2026, for Q2 FY27 Results
Jubilant Pharmova's trading window closes October 1, 2026, for Q2 FY27 results. It will reopen 48 hours post-announcement. The Board Meeting date for results approval is yet to be intimated.
Read the summary - Low impact
Jubilant Pharmova: Final Dividend for FY26 Withheld for Shareholders Lacking KYC
Jubilant Pharmova is withholding the final dividend for FY26 due to incomplete KYC details from shareholders holding physical shares. Shareholders must update their KYC and bank details as per SEBI regulations to receive the payment electronically.
Read the summary - Medium impact
Jubilant Pharmova: USFDA Classifies Spokane Facility as VAI
Jubilant Pharmova's subsidiary, Jubilant HollisterStier LLC's CMO facility in Spokane, Washington, USA, has been classified as 'Voluntary Action Indicated (VAI)' by the USFDA. This classification follows an inspection conducted between June 8-17, 2026. The company received the Establishment Inspection Report (EIR) on September 10, 2026.
Read the summary - Medium impact
Jubilant Pharmova Receives GST Show Cause Notice for ₹87.31 Crore
Jubilant Pharmova received a GST Show Cause Notice proposing a demand of ₹87.31 Crore (₹33.58 Cr GST, ₹20.15 Cr interest, ₹33.58 Cr penalty) for FY23. The notice was received on August 31, 2026. The company plans to contest the notice and expects no financial impact.
Read the summary - Low impact
Jubilant Pharmova Announces Special Window for Share Transfer & KYC Update
Jubilant Pharmova Limited published newspaper ads on August 29, 2026. The ads detail a special window for re-lodging physical share transfer requests and emphasize KYC updation and dematerialization of physical share certificates.
Read the summary - Medium impact
Jubilant Generics Receives GST Show Cause Notice for ₹105.5 Crore Demand
Jubilant Generics Limited received a Show Cause Notice from CGST, Roorkee, proposing a demand of ₹52.75 crore GST and ₹52.75 crore penalty for FY21-22. The company contests the notice, citing alleged violation of IGST refund and Advance Authorisation scheme rules. Jubilant expects no financial impact.
Read the summary - Medium impact
Jubilant Pharmova Limited Holds 48th AGM; All Resolutions Passed
Jubilant Pharmova Limited held its 48th AGM on August 26, 2026, via VC/OAVM. All resolutions were passed. The company reported FY26 consolidated revenue of ₹83 billion, up 14%, and EBITDA of ₹13 billion, up 8%. Q1 FY27 revenue grew 17% to ₹22 billion. A dividend of ₹5 per share was recommended.
Read the summary - Medium impact
Jubilant Pharmova gets USFDA nod for Spokane facility's Line 3
Jubilant Pharmova's subsidiary, Jubilant HollisterStier LLC, received USFDA approval for commercial batch manufacturing on its new Isolator-based fill and finish line, Line 3, at its Spokane, U.S.A. facility. This approval allows for the production of the first product on this line.
Read the summary - Medium impact
Jubilant Pharmova shareholders approve re-appointments of MD & JMD
Jubilant Pharmova Limited shareholders approved the re-appointment of Mr. Priyavrat Bhartia as MD and Mr. Arjun Shanker Bhartia as JMD. Both resolutions passed with over 99% of votes in favor. The postal ballot concluded on August 17, 2026.
Read the summary - Low impact
Jubilant Pharmova Publishes Unaudited Q1 FY27 Financial Results
Jubilant Pharmova Limited published its unaudited standalone and consolidated financial results for the quarter ended June 30, 2026. The results were approved by the Board on August 10, 2026, and published on August 11, 2026.
Read the summary - Medium impact
Jubilant Pharmova Q1FY27 Revenue Up 17% to ₹2,229 Cr, PAT Declines
Jubilant Pharmova reported Q1 FY27 revenue of ₹2,229 Cr, up 17% YoY. PAT declined 45% to ₹56 Cr due to lower margins from SPECT radiopharmaceuticals and higher costs. The company anticipates margin improvement in H2 FY27. Investments in new PET facilities and progress in novel drug trials continue.
Read the summary - Medium impact
Jubilant Pharmova Q1 FY27 Results: Consolidated Profit Declines to ₹564 Crore
Jubilant Pharmova reported unaudited consolidated results for Q1 FY27. Revenue from operations was ₹22,294 crore and profit after tax was ₹564 crore. Standalone revenue was ₹671 crore with a profit of ₹73 crore. The results were approved by the Board on August 10, 2026.
Read the summary - Low impact
Jubilant Pharmova to Meet Investors Aug 13-14, Discuss Q1 FY27 Results
Jubilant Pharmova management to meet institutional investors on August 13-14, 2026, as part of Emkay Confluence. They will discuss the Q1 FY27 Earnings presentation. Q1 FY27 financial results will be disclosed on August 10, 2026.
Read the summary - Low impact
Jubilant Pharmova Announces 48th AGM, E-voting, Record Date, and Final Dividend Info
Jubilant Pharmova Limited announced its 48th AGM details, including e-voting and final dividend information. Email dissemination of the AGM notice and FY26 Annual Report was completed on August 1, 2026. Advertisements were published on August 2, 2026.
Read the summary - Low impact
Jubilant Pharmova to Deduct TDS on Final Dividend for FY26
Jubilant Pharmova Limited will deduct TDS on its final dividend for FY26, recommended at ₹5 per equity share. The record date is July 24, 2026. Shareholders must submit required tax documents by August 14, 2026, to avail beneficial rates. Non-resident shareholders have specific documentation requirements.
Read the summary - Low impact
Jubilant Pharmova to hold 48th AGM on Aug 26, dispatches Annual Report for FY26
Jubilant Pharmova Limited will hold its 48th AGM on August 26, 2026. The company has dispatched its Annual Report for FY 2025-26 and the AGM notice to shareholders. Shareholders are advised to update their email addresses for electronic communication.
Read the summary - Low impact
Jubilant Pharmova Announces 48th AGM on Aug 26, 2026, Proposes ₹5 Dividend
Jubilant Pharmova Limited will hold its 48th AGM on August 26, 2026, via VC/OAVM. The company proposes a ₹5 per equity share dividend for FY 2025-26 and will adopt FY26 financial statements. Cut-off for voting is August 19, 2026, with remote e-voting from August 23-25, 2026.
Read the summary - Low impact
Jubilant Pharmova Files Newspaper Ads for Share Transfer to IEPF
Jubilant Pharmova published newspaper ads on July 30, 2026, concerning the transfer of equity shares and dividends to the IEPF. The information is also available on the company's website.
Read the summary - Low impact
Jubilant Pharmova: Unclaimed Dividends & Shares Due for IEPF Transfer by Oct 31
Jubilant Pharmova will transfer unpaid dividends and shares to IEPF by October 31, 2026. Shareholders must claim by August 31, 2026. This includes unclaimed dividends from FY 2018-19 and old share certificates. Details are on the company website.
Read the summary - Low impact
Jubilant Pharmova Announces 48th AGM on August 26, 2026
Jubilant Pharmova Limited's 48th AGM is scheduled for August 26, 2026. The meeting will be held via video conference. The Annual Report for FY2025-26 will be shared with shareholders and uploaded to the company website.
Read the summary - Low impact
Jubilant Pharmova Submits Newspaper Ads for Postal Ballot Completion
Jubilant Pharmova Limited has completed the dispatch of postal ballot notices. Newspaper advertisements confirming this were published on July 19, 2026. The information is available on the company's website.
Read the summary - Medium impact
Jubilant Pharmova: Shareholders to Vote on Re-appointment of MD and JMD via Postal Ballot
Jubilant Pharmova is seeking shareholder approval via postal ballot for re-appointing Mr. Priyavrat Bhartia as MD and Mr. Arjun Shanker Bhartia as JMD for three years. E-voting runs from July 19 to August 17, 2026. Mr. Priyavrat Bhartia's remuneration is proposed up to ₹7.5 crore annually.
Read the summary - Low impact
Jubilant Pharmova Grants 2,07,003 Stock Options to Employees
Jubilant Pharmova granted 2,07,003 stock options, RSUs, and PSUs to employees. The grant includes options with an exercise price of ₹974.45 and others at Re. 1. Vesting periods vary, with some options vesting over time and others on April 01, 2029. The plan complies with SEBI regulations.
Read the summary - Medium impact
Jubilant Pharmova: Income Tax Demand of ₹22.10 Crore Deleted
Jubilant Pharmova's ₹22.10 crore income tax demand for AY 2020-21 has been deleted following a rectification order received on July 15, 2026. The company is pursuing separate appeals on merit grounds.
Read the summary - Low impact
Jubilant Pharmova Files SEBI Reg 74(5) Certificate for Q1FY27
Jubilant Pharmova Limited submitted a SEBI Regulation 74(5) certificate for the quarter ended June 30, 2026. The certificate confirms dematerialization and cancellation of share certificates. This is a routine compliance filing received from the company's Registrar and Share Transfer Agent, Alankit Assignments Limited.
Read the summary - Low impact
Jubilant Pharmova: Newspaper Ads on Share Transfer, KYC, and IEPF Campaign
Jubilant Pharmova published newspaper ads on June 30, 2026, regarding a special window for physical share transfer re-lodgement. It also covers KYC updation, dematerialization of physical shares, and the second 100-day IEPF Campaign “Saksham Niveshak”. Information is available on the company website.
Read the summary - Low impact
Jubilant Pharmova: Trading Window Closed for Q1 FY27 Results
Jubilant Pharmova Limited will close its trading window from July 01, 2026, until 48 hours post Q1 FY27 results announcement. This is in compliance with SEBI insider trading regulations. The board meeting date for results declaration will be announced later.
Read the summary - Medium impact
Jubilant Pharmova Subsidiary Gets Tentative USFDA Approval for Pantoprazole
Jubilant Pharmova subsidiary, Jubilant Generics, received tentative USFDA approval for Pantoprazole Sodium Delayed Release Oral Suspension. Final approval is expected upon patent expiry in December 2026.
Read the summary - Medium impact
Jubilant Pharmova Completes USFDA Inspection with 8 Observations
Jubilant Pharmova's subsidiary, Jubilant HollisterStier LLC, completed a USFDA inspection at its Spokane, WA facility on June 17, 2026. The inspection resulted in eight observations, none related to sterility assurance. The company will respond within 15 business days.
Read the summary - Medium impact
Jubilant Pharmova: USFDA Issues Warning Letter for Montreal Facility
Jubilant Pharmova's subsidiary, JHSGP, received a Warning Letter from the USFDA following an inspection of its Montreal, Canada facility. The company is implementing corrective actions and operations continue under enhanced controls.
Read the summary - High impact
Jubilant Pharmova Releases Q4FY26 Transcript; Revenue Up 19% to ₹2,290 Cr
Jubilant Pharmova's Q4FY26 revenue rose 19% to ₹2,290 Cr, with FY26 revenue up 14% to ₹8,280 Cr. EBITDA increased 2% to ₹363 Cr in Q4 and 8% to ₹1,326 Cr for FY26. The company anticipates strengthened growth in FY27 and improved EBITDA margins from H2 FY27. CDMO Line 3 is expected to yield $80-90M peak revenue.
Read the summary - Low impact
Jubilant Pharmova Publishes Audited Financial Results for FY26
Jubilant Pharmova Limited published its audited standalone and consolidated financial results for the quarter and year ended March 31, 2026. The Board approved the results on May 22, 2026. The full results are available on the company website and stock exchange platforms.
Read the summary - Low impact
Jubilant Pharmova: Audio Recording of FY26 Q4 Earnings Webinar Uploaded
Jubilant Pharmova uploaded the audio recording of its earnings webinar for the quarter and year ended March 31, 2026. The webinar, held on May 22, 2026, covered both standalone and consolidated financial results. The recording is available on the company's website.
Read the summary - Medium impact
Jubilant Pharmova Subsidiary Faces ₹107.89 Crore Tax Adjustment; Company to Appeal
Jubilant Generics Limited, a subsidiary of Jubilant Pharmova, received a ₹107.89 crore tax adjustment order from the Income-tax department for FY23. The company will appeal the order, expecting relief and no material financial implications, though a ₹37.70 crore reduction in Deferred Tax Assets is possible.
Read the summary - Medium impact
Jubilant Pharmova re-appoints Priyavrat Bhartia and Arjun Shanker Bhartia as MDs
Jubilant Pharmova re-appointed Priyavrat Bhartia as Managing Director and Arjun Shanker Bhartia as Joint Managing Director for three years from June 1, 2026, subject to shareholder approval. Both have extensive experience and have been instrumental in the company's strategy.
Read the summary - Medium impact
Jubilant Pharmova Appoints Ashish Mukkirwar as New CFO, Arun Sharma Moves to Advisor Role
Jubilant Pharmova Limited appointed Ashish Mukkirwar as its new CFO and KMP, effective May 23, 2026. Outgoing CFO, Arun Kumar Sharma, will move to an Advisor role. Mukkirwar brings over 20 years of financial leadership experience.
Read the summary - High impact
Jubilant Pharmova FY26 Revenue Up 14% to ₹8,280 Cr; Board Proposes ₹5 Dividend
Jubilant Pharmova reported FY26 revenue of ₹8,280 Cr, up 14% YoY, driven by CDMO Sterile Injectables. Q4 FY26 revenue increased 19% to ₹2,290 Cr. The company proposed a dividend of ₹5 per share. Investments in PET manufacturing and strategic partnerships are underway to support Vision 2030.
Read the summary - Medium impact
Jubilant Pharmova Appoints Ashish Mukkirwar as New CFO, Sharma Moves to Advisor Role
Jubilant Pharmova appoints Ashish Mukkirwar as CFO effective May 23, 2026. Arun Kumar Sharma resigns as CFO on May 22, 2026, moving to an Advisor role. Mukkirwar has over 20 years of financial leadership experience.
Read the summary - Medium impact
Jubilant Pharmova Re-appoints Priyavrat Bhartia and Arjun Shanker Bhartia as MDs
Jubilant Pharmova Limited's Board approved the re-appointment of Priyavrat Bhartia as MD and Arjun Shanker Bhartia as Joint MD. Both will serve for three years from June 1, 2026, pending shareholder approval. This decision was made during a board meeting on May 22, 2026.
Read the summary - Medium impact
Jubilant Pharmova Appoints Ashish Mukkirwar as New CFO, Arun Sharma Moves to Advisor Role
Jubilant Pharmova appointed Ashish Mukkirwar as CFO effective May 23, 2026. Arun Kumar Sharma resigned as CFO on May 22, 2026, moving to an advisor role. Mukkirwar has over 20 years of financial leadership experience.
Read the summary - Medium impact
Jubilant Pharmova Recommends 500% Final Dividend; Sets July 24 Record Date
Jubilant Pharmova approved audited financial results for FY26. The Board recommended a final dividend of 500% (₹5 per share). July 24, 2026, is set as the record date for dividend payment. Auditors issued an unmodified opinion.
Read the summary - Medium impact
Jubilant Pharmova Recommends 500% Final Dividend; Audited Results Approved
Jubilant Pharmova's Board approved audited FY26 results and recommended a final dividend of 500% (₹5 per share). The record date for dividend payment is July 24, 2026. Auditors issued an unmodified opinion on the results.
Read the summary - Medium impact
Jubilant Pharmova Recommends 500% Dividend, Approves FY26 Audited Results
Jubilant Pharmova's Board approved audited financial results for FY26. A final dividend of 500% (₹5 per share) was recommended. July 24, 2026, is the record date for dividend payment.
Read the summary - Medium impact
Jubilant Pharmova to meet investors on May 28, 2026, to discuss Q4 FY26 results
Jubilant Pharmova Limited management will meet institutional investors on May 28, 2026. The meetings, part of 360 One Capital's conference, will discuss the Q4 FY26 Earnings presentation. The company will disclose its Q4 FY26 financial results and file the presentation on May 22, 2026.
Read the summary - Low impact
Jubilant Pharmova to discuss Q4 FY26 results with investors on May 25, 2026
Jubilant Pharmova Limited will host analysts and institutional investors on May 25, 2026. Discussions will include the Q4 FY26 Earnings presentation, which will be filed on May 22, 2026, after the release of financial results.
Read the summary - Low impact
Jubilant Pharmova Publishes Newspaper Ads on Investor Campaign, Share Transfer, and KYC
Jubilant Pharmova published newspaper ads on April 29, 2026, regarding the 'Saksham Niveshak' investor campaign, a special window for physical share transfer re-lodgement, and KYC updation for physical shares. Information is also available on the company website.
Read the summary - Low impact
Jubilant Pharmova to host FY26 Earnings Webinar on May 22, 2026
Jubilant Pharmova Limited will host an Earnings Webinar on May 22, 2026, to discuss its FY26 financial performance. The event will feature management commentary and a Q&A session. All investors are invited to attend the webinar, which will be held on Zoom.
Read the summary - Low impact
Jubilant Pharmova to Host Earnings Webinar on May 22, 2026, for FY26 Performance
Jubilant Pharmova Limited will host an Earnings Webinar on May 22, 2026, to discuss FY26 financial performance. The event includes management commentary and a Q&A session. Registration is mandatory.
Read the summary
Model portfolios
Filings are the raw material. These are what SEBI-registered experts build from them.
- Stocks
All-Terrain
One equity portfolio instead of three: large, mid and small cap in a single book.
Moderate-Aggressive34 holdings3+ yearsView portfolio - Stocks
Core Compounders
Companies that have already been through a downturn and came out still growing.
Moderate20 holdings3+ yearsView portfolio - Stocks
Udaan
Fast-growing, less-covered companies still early in their runway.
Aggressive29 holdings5+ yearsView portfolio - Stocks
Bharat Rising
Built around India's own shifts: capex, household savings, energy and consumption.
Moderate-Aggressive25 holdings3+ yearsView portfolio